Bifogade filer
PDF
Kurs
-17,79%
Kurs
-17,79%
Open
2,23
High
2,23
Low
1,74
Close
1,82
Kursutveckling under dagen för detta pressmeddelande
(SEK).
Likviditet
0,22 MSEK
Likviditet
0,22 MSEK
Rel. mcap
0,49%
Antal aktier
118 171
Likviditet under dagen för detta pressmeddelande
Kalender
| Est. tid* | ||
| 2026-03-03 | 08:30 | Bokslutskommuniké 2025 |
| 2025-11-04 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-12 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-14 | N/A | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2025-05-13 | N/A | Årsstämma |
| 2025-05-06 | - | Kvartalsrapport 2025-Q1 |
| 2025-03-04 | - | Bokslutskommuniké 2024 |
| 2024-11-05 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-13 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-15 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2024-05-14 | - | Årsstämma |
| 2024-05-07 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-05 | - | Bokslutskommuniké 2023 |
| 2023-10-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-15 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-17 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2023-05-16 | - | Årsstämma |
| 2023-03-07 | - | Bokslutskommuniké 2022 |
| 2022-11-22 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-16 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-05-03 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-08 | - | Bokslutskommuniké 2021 |
| 2021-11-02 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-17 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-25 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2021-05-24 | - | Årsstämma |
| 2021-05-04 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-08 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-20 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2020-05-19 | - | Årsstämma |
| 2020-05-13 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-12 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-12 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-09 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2019-05-08 | - | Årsstämma |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-19 | - | Extra Bolagsstämma 2019 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-15 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-15 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-15 | - | Extra Bolagsstämma 2018 |
| 2018-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-01 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2018-02-28 | - | Årsstämma |
| 2018-01-30 | - | Bokslutskommuniké 2017 |
| 2017-05-31 | - | Extra Bolagsstämma 2017 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2025-05-06 08:30:00
Scandinavian ChemoTech AB (publ) hereby publishes the Interim Report for Q1 2025.
First-quarter sales reached 2 472 KSEK, which is the best quarter so far. All sales originated from Animal Care.
The report is attached to this press release and can also be downloaded from the company's website.
First quarter 2025
- Net sales amounted to 2 472 KSEK (1 345)
- Profit/loss after financial items amounted to -3 322 KSEK (-3 203)
- Earnings per share amounted to -0,14 SEK (-0,18)
- Cash flow from operating activities amounted to -1 239 KSEK (-4 853)
- All orders were delivered by the end of the period
Events during the reporting period
- ChemoTech implements management changes to reduce costs.
- ChemoTech's Animal Care operations showed positive cashflow for 2024 in separate reporting.
- ChemoTech restructures loans and doubles the duration to 12 months.
- ChemoTech secures a new order and expands Animal Care Operations through global collaboration in equine oncology
Events after the reporting period
- ChemoTech starts 2025 strong with Q1 order intake exceeding USD 230,000.
- Animal Care expands U.S. presence with new partnership, securing an order of appr. USD 66,000.
- ChemoTech's Animal Care celebrates record-breaking month with order intake of 200,000 USD in April.
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 06-05-2025 08:30 CET.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Certified Adviser: Redeye AB